Print

BioGenes Reports Strong Growth of HCP Assay Development Business  
2/28/2013 11:06:46 AM

Berlin, Germany, February 28, 2013 / B3C newswire / - BioGenes GmbH, a global leader in host cell protein (HCP) assay development, announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.

BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development. “Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”

About BioGenes

BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world.

Contact

Dagmar Schwertner-Knoll

Marketing/Sales Director

BioGenes GmbH

+49-30-65762380

d.schwertner@biogenes.de

Media contact

Dr. Sabine Duntze

B3C Group GmbH

+41 41 612 2110

sd@b3cgroup.com


//-->